Cardiff Oncology (NASDAQ:CRDF) is a biotechnology firm focused on developing new treatment options for cancer patients. Concentrating on oncology, the company leverages scientific innovations to create targeted solutions aiming to address the unmet needs within the cancer treatment landscape. Cardiff Oncology is particularly known for its commitment to advancing its lead drug candidate, onvansertib, through various phases of clinical trials in combination with standard-of-care therapies. The objective is to improve patient outcomes in cancers with significant unmet need, including colorectal, pancreatic, and prostate cancers. Its projects are designed to disrupt cancer cell growth and resistance, demonstrating the company's dedication to pushing the boundaries of cancer treatment. Through strategic partnerships and ongoing research, Cardiff Oncology seeks to unlock new possibilities in oncology, providing hope and new options for patients and their families.